| Revenue growth | FY26 revenue up 12.3% to ₹1,875cr; H2 outperformed H1 by 21%. |
|---|---|
| Margins | Gross margins expanded 128bps to 68%; Q4 consolidated EBITDA at 21%. |
| Demand visibility | Strong domestic and international demand; visibility improving in US and Europe. |
| Management confidence | Confident but cautious regarding global geopolitical volatility and raw material inflation. |
Growth
FY26 consolidated revenue rose 12.3% to ₹1,875cr; H2 grew 21% over H1, meeting prior H2 guidance.
Outlook
FY27 revenue guidance is ₹2,300-₹2,400cr (22-28% growth); EBITDA margins guided at 23-25%.
Risks
Raw material costs surged 20% due to crude prices; geopolitical disruptions in Red Sea impact logistics.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,724.40
- Market cap
- ₹17,479 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 55.5×Sector 57.8×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Investor Presentation: Key Takeaways
Poly Medicure reported strong Q1 FY27 consolidated revenue growth of 30.3% YoY, driven by acquisitions (Citieffe, PendraCare) and domestic expansion. Strategy shifts towards high-complexity medical devices like Cardiology and Orthopaedics.
- Call
- Guides 100% growth
Poly Medicure Q1 FY27 Results: Net Profit ₹85.3 Cr, Down 8.4% YoY
Poly Medicure Ltd reported revenue from operations of ₹525.4 Cr (+30.3% YoY) and net profit of ₹85.3 Cr (-8.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹85.3 Cr · -8.4% YoY
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure reported FY26 consolidated revenue of ₹1,875cr (up 12.3%) and standalone EBITDA of ₹446cr (26.8% margin). The company is transitioning from product-focused to therapy-focused segments like Cardiology and Renal.
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure (Polymed) reported FY26 consolidated revenue growth of 12.3% YoY. The company is transitioning towards high-end technology segments like Cardiology and Orthopaedics through strategic European acquisitions (Citieffe, PendraCare).